Supplementary Information

Novel 4-aminoquinoline-pyrimidine based hybrids with improved *in vitro* and *in vivo* antimalarial activity

Sunny Manohar,⁺ U. Chinna Rajesh,⁺ Shabana I. Khan,^{‡,§} Babu L. Tekwani^{‡,#} and Diwan S. Rawat^{*,+}

 *Department of Chemistry, University of Delhi, Delhi-110007, INDIA
*National Centre for Natural Products Research,
*Department of Pharmacognosy, and #Department of Pharmacology, School of Pharmacy, University of Mississippi, MS-38677, USA

List of Contents

Experimental details and characterization of new compounds	2-8
Assay for <i>in-vitro</i> antimalarial activity and cytotoxicity	8-9
Crystallographic data	9-10
References	11
¹ H and ¹³ C NMR of compounds	12-43
HPLC of compounds	44-51

Experimental

Chemistry

All of the chemicals used in the synthesis were purchased from Sigma-Aldrich and were used as such. Thin layer chromatography was used to monitor the progress of the reactions and checked by precoated TLC plates (E. Merck Kieselgel 60 F_{254}) with spots being visualized by iodine vapors. Compounds were purified over silica gel (60-120 mesh) column or recrystallized with suitable solvents. Solvents were distilled before using for purification purposes. Meting points were recorded on an ERS automated melting point apparatus and are uncorrected. IR spectra were recorded using Perkin-Elmer and Bruker FT-IR and the values are expressed as λ_{max} cm⁻¹. Mass spectral data were recorded on a Jeol-AccuTOF JMS-T100LC and micromass LCT Mass Spectrometer/Data system. The ¹H NMR and ¹³C NMR spectra were recorded on Jeol Spectrospin spectrometer at 400 MHz and 100 MHz respectively using TMS as an internal standard. The chemical shift values are recorded on δ scale and the coupling constants (J) are in Hz. HPLC was done using Waters HPLC system, 25 cm C18 column, and a run time of 60 min.

General procedure for the synthesis of compounds 6a-d and 7a-d

To a well stirred solution of 2,4-dichloro-6-methyl-pyrimidine (2.0 g, 12.2 mmol) and triethylamine (2.48 g, 24.5 mmol) in ethanol (50 ml) at room temperature was added diamines **5a-d** (12.2 mmol). The reaction mixture was allowed to stir overnight at room temperature. After completion of reaction as evident by TLC, reaction mixture was poured into ice cold water (250 ml) and precipitate thus formed was filtered and washed with excess of water at vaccum pump. The crude precipitate was then dried, dissolved in 100 ml of CHCl₃ and extracted with water (2 × 500 ml) and finally with brine. Excess of solvent was evaporated to dryness under vaccum and the crude product thus obtained was purified by SiO₂ column using MeOH/CHCl₃ as eluent to yield respective compounds **6a-d** and **7a-d**.

N-(2-chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-ethane-1,2-diamine

(6a): White solid; Yield: 75 %; mp 220-222 °C; IR (cm⁻¹, KBr): 3269, 2954, 1581, 1434, 1234, 1105, 848; ¹H NMR (400 MHz, DMSO-*d*₆): 2.20 (s, 3H), 3.39-3.46 (m, 4H), 6.57 (s, 1H), 6.71 (d, 1H, *J* = 5.5 Hz), 7.37 (brs, 1H), 7.41 (dd, 1H, *J* = 11.0 Hz, 2.0 Hz), 7.65 (brs, 1H), 7.74 (d, 1H, *J* = 2.3 Hz), 8.15 (d, 1H, *J* = 8.7 Hz), 8.37 (d, 1H, *J* = 5.5 Hz); ESI-MS

(m/z): 348.10 $(M+H)^+$; Anal. Calcd for $C_{16}H_{15}C_{12}N_5$: C, 55.19; H, 4.34; N, 20.11; Found: C, 55.28; H, 4.30; N, 20.13. HPLC purity: 98.6 %

N-(2-Chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-propane-1,3-diamine (**6b**): Pale yellow solid; Yield: 78 %; mp 192-194 °C; IR (cm⁻¹, KBr): 3263, 3062, 2963, 1583, 1363, 1280, 1100, 848; ¹H NMR (400 MHz, DMSO-*d*₆): 1.88 (quin, 2H), 2.18 (s, 3H), 3.28-3.33 (m, 4H), 6.44 (d, 1H, J = 5.4 Hz), 6.53 (s, 1H), 7.28 (brs, 1H), 7.42 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.63 (brs, 1H), 7.75 (d, 1H, J = 2.3 Hz), 8.23 (d, 1H, J = 9.1 Hz), 8.35 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, DMSO-*d*₆): 24.48, 28.16, 39.80, 41.05, 99.58, 108.78, 118.39, 124.94, 124.98, 128.39, 134.30, 149.96, 150.94, 152.76, 160.84, 163.03, 170.59; ESI-MS (m/z): 362.11 (M+H)⁺; Anal. Calcd for C₁₇H₁₇C₁₂N₅: C, 56.36; H, 4.73; N, 19.33 Found: C, 56.42; H, 4.74; N, 19.38; HPLC purity: 98.4 %

N-(2-Chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-butane-1,4-diamine (6c): White solid; Yield: 70 %; mp 156-158 °C; IR (cm⁻¹, KBr): 3286, 2955, 1581, 1367, 1290, 1137, 1102, 871; ¹H NMR (400 MHz, CDCl₃): 1.73-1.87 (m, 4H), 2.28 (s, 3H), 3.37 (q, 2H), 3.52 (q, 2H), 5.13 (brs, 1H), 5.30 (brs, 1H), 6.41 (d, 1H, J = 5.5 Hz), 6.45 (s, 1H), 7.34 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.66 (d, 1H, J = 8.7 Hz), 7.95 (d, 1H, J = 2.3 Hz), 8.52 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 376.33 (M+H)⁺; Anal. Calcd for C₁₈H₁₉C₁₂N₅: C, 57.45; H, 5.09; N, 18.61 Found: C, 57.39; H, 5.16; N, 18.62; HPLC purity: 99.0 %

N-(2-Chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-hexane-1,6-diamine (6d): Off white solid; Yield: 80 %; mp 103-105 °C; IR (cm⁻¹, KBr): 3277, 3065, 2937, 1581, 1366, 1291, 1078, 849, 797; ¹H NMR (400 MHz, CDCl₃): 1.45-1.55 (m, 4H), 1.60-1.67 (m, 2H), 1.73-1.81 (m, 2H), 2.29 (s, 3H), 3.31 (q, 4H), 3.43 (q, 4H), 4.96 (brs, 1H), 5.14 (brs, 1H), 6.41 (d, 1H, J = 5.5 Hz), 6.43 (s, 1H), 7.36 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.65 (d, 1H, J = 8.7 Hz), 7.96 (d, 1H, J = 2.3 Hz), 8.53 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 404.11 (M+H)⁺; Anal. Calcd for C₂₀H₂₃C₁₂N₅: C, 59.41; H, 5.73; N, 17.32 Found: C, 59.44; H, 5.71; N, 17.31; HPLC purity: 97.1 %

N-(4-chloro-6-methyl-pyrimidin-2-yl)-N'-(7-chloro-quinolin-4-yl)-ethane-1,2-diamine

(7a): White solid; Yield: 22 %; mp 208-210 °C; IR (cm⁻¹, KBr): 3257, 2969, 1584, 1432, 1368, 1248, 1140, 973; ¹H NMR (400 MHz, DMSO- d_6): 2.13 (s, 3H), 3.41-3.48 (m, 4H), 6.25 (s, 1H), 6.70 (d, 1H, J = 5.4 Hz), 7.32 (brs, 1H), 7.41 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.74 (d, 1H, J = 2.3 Hz), 7.91 (brs, 1H), 8.16 (d, 1H, J = 8.7 Hz), 8.37 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, DMSO- d_6): 22.87, 38.29, 41.33, 98.89, 102.94, 117.44, 124.00, 124.17, 127.42, 133.49, 148.95, 150.11, 151.80, 159.46, 164.05, 165.43; ESI-MS (m/z): 348.10

(M+H)⁺; Anal. Calcd for C₁₆H₁₅C₁₂N₅: C, 55.19; H, 4.34; N, 20.11; Found C, 55.15; H, 4.32; N, 20.21; HPLC purity: 98.7 %

N-(4-Chloro-6-methyl-pyrimidin-2-yl)-N'-(7-chloro-quinolin-4-yl)-propane-1,3-diamine (**7b**): Pale yellow solid; Yield: 15 %; mp 172-174 °C; IR (cm⁻¹, KBr): 3264, 3063, 2964, 1583, 1364, 1280, 1100, 863; ¹H NMR (400 MHz, DMSO-*d*₆): 1.89 (quin, 2H), 2.14 (s, 3H), 3.24-3.35 (m, 4H), 6.25 (s, 1H), 6.46 (d, 1H, J = 5.4 Hz), 7.28 (brs, 1H), 7.43 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.76 (d, 1H, J = 2.3 Hz), 7.81 (brs, 1H), 8.25 (d, 1H, J = 9.1 Hz), 8.37 (d, 1H, J = 9.1 Hz); ¹³C NMR (100 MHz, DMSO-*d*₆): 22.85, 27.22, 38.01, 40.12, 98.71, 102.79, 117.48, 124.09, 127.46, 133.43, 149.03, 150.04, 151.84, 159.51, 164.00, 165.04, 167.75; ESI-MS (m/z): 362.12 (M+H)⁺; Anal. Calcd for C₁₇H₁₇C₁₂N₅: C, 56.36; H, 4.73; N, 19.33; Found: C, 56.37; H, 4.76; N, 19.41.

N-(4-Chloro-6-methyl-pyrimidin-2-yl)-N'-(7-chloro-quinolin-4-yl)-butane-1,4-diamine (7c): White solid; Yield: 25 %; mp 175-177 °C; IR (cm⁻¹, KBr): 3251, 3127, 2957, 1589, 1367, 1234, 1139, 972, 847; ¹H NMR (400 MHz, CDCl₃): 1.79-1.82 (m, 4H), 2.31 (s, 3H), 3.36-3.40 (m, 4H), 5.13 (brs, 1H), 5.30 (brs, 1H), 6.06 (s, 1H), 6.39 (d, 1H, J = 5.5 Hz), 7.35 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.66 (d, 1H, J = 8.7 Hz), 7.95 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 22.71, 24.83, 25.97, 41.88, 97.93, 102.13, 116.81, 122.29, 123.74, 127.18, 133.63, 148.36, 149.67, 151.09, 159.26, 163.55, 164.25; ESI-MS (m/z): 376.16 (M+H)⁺; Anal. Calcd for C₁₈H₁₉C₁₂N₅: C, 57.45; H, 5.09; N, 18.61; Found: C, 57.50; H, 5.10; N, 18.67.

N-(4-Chloro-6-methyl-pyrimidin-2-yl)-N'-(7-chloro-quinolin-4-yl)-hexane-1,6-diamine

(7d): White solid; Yield: 18 %; mp 99-101 °C; IR (cm⁻¹, KBr): 3108, 2941, 1580, 1366, 1280, 1221, 1163, 972; ¹H NMR (400 MHz, CDCl₃): 1.41-1.53 (m, 4H), 1.59-1.67 (m, 2H), 1.73- 1.79 (m, 2H), 2.30 (s, 3H), 3.27-3.32 (m, 4H), 4.97 (brs, 1H), 5.16 (brs, 1H), 6.04 (s, 1H), 6.39 (d, 1H, J = 5.5 Hz), 7.34 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.64 (d, 1H, J = 8.7 Hz), 7.94 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 404.38 (M+H)⁺; Anal. Calcd for C₂₀H₂₃C₁₂N₅: C, 59.41; H, 5.73; N, 17.32; Found: C, 59.35; H, 5.80; N, 17.31; HPLC purity: 98.1 %

General Procedure for the synthesis of compounds 8a-n

In a 100 ml round bottom flask, compound **6a-d** (1 eq.) was taken and dissolved in 10 ml of DMF. To this, a solution of respective amine (3 eq.) in DMF (5 ml) was added dropwise. Reaction mixture was allowed to stir at 100-120 °C for 10 hours monitored by TLC. After completion, water (50 ml) was added to reaction mixture and it was extracted with EtOAc (2 \times 25 ml). Organic layer was then collected, washed with water (2 \times 100 ml) and brine, dried

over Na_2SO_4 and finally excess of solvent was evaporated under vaccum. The crude residue thus obtained was purified by SiO_2 column using MeOH/CHCl₃ as eluent to afford respective compounds **8a-n**.

N-(7-chloro-quinolin-4-yl)-N'-(6-methyl-2-piperidin-1-yl-pyrimidin-4-yl)-ethane-1,2diamine (8a): White solid. Yield: 85 %; mp 177-179 °C; IR (cm⁻¹, KBr): 3385, 3344, 2941, 1580, 1447, 1331, 1237, 1141, 790; ¹H NMR (400 MHz, DMSO-*d*₆): 1.36-1.49 (m, 6H), 2.02 (s, 3H), 3.31-3.41 (m, 8H), 5.85 (s, 1H), 6.56-6.72 (m, 2H), 7.34 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.41 (brs, 1H), 7.68 (d, 1H, J = 2.3 Hz); 8.07 (d, 1H, J = 8.7 Hz), 8.28 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 397.22 (M+H)⁺; Anal. Calcd for C₂₁H₂₅ClN₆: C, 63.55; H, 6.35; N, 21.17; Found: C, 63.53; H, 6.39; N, 21.26; HPLC purity: 99.7 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-piperidin-1-yl-pyrimidin-4-yl)-propane-1,3diamine (8b): Pale yellow solid; Yield: 82 %; mp 194-196 °C; IR (cm⁻¹, KBr): 3241, 3079, 1940, 1615, 1587, 1361, 1208, 1001, 804; ¹H NMR (400 MHz, CDCl₃): 1.46-1.56 (m, 6H), 1.87 (quin, 2H), 2.16 (s, 3H), 3.36 (q, 2H), 4.45 (t, 4H), 3.49 (q, 2H), 4.86 (brs, 1H), 5.72 (s, 1H), 5.92 (brs, 1H), 6.32 (d, 1H, J = 5.4 Hz), 7.22 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.66 (d, 1H, J = 8.7 Hz), 7.85 (d, 1H, J = 2.3 Hz), 8.41 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.36, 24.67, 25.45, 29.06, 38.55, 40.34, 44.89, 92.36, 98.86, 117.43, 121.55, 124.83, 128.53, 134.63, 149.18, 149.91, 151.96, 162.42, 162.84, 165.62; ESI-MS (m/z): 411.23 (M+H)⁺; Anal. Calcd for C₂₂H₂₇ClN₆: C, 64.30; H, 6.62; N, 20.45; Found: C, 64.42; H, 6.68; N, 20.41; HPLC purity: 99.1 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-piperidin-1-yl-pyrimidin-4-yl)-butane-1,4diamine (8c): White solid; Yield: 88 %; mp 187-189 °C; IR (cm⁻¹, KBr): 3247, 3067, 2935, 1581, 1364, 1210, 1079, 848; ¹H NMR (400 MHz, CDCl₃): 1.49-1.65 (m, 6H), 1.73-1.79 (m, 2H), 1.83-1.89 (m, 2H), 2.17 (s, 3H), 3.35 (q, 2H), 3.45-3.52 (m, 6H), 4.79 (brs, 1H), 5.25 (brs, 1H), 5.76 (s, 1H), 6.38 (d, 1H, J = 5.5 Hz), 7.31 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.63 (d, 1H, J = 8.7 Hz), 7.93 (d, 1H, J = 2.3 Hz), 8.50 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.09, 24.67, 25.43, 25.75, 27.64, 40.64, 43.02, 44.87, 91.91, 98.92, 117.14, 121.21, 125.04, 128.56, 134.66, 149.05, 149.76, 151.93, 162.17, 162.90, 165.67; ESI-MS (m/z): 425.31 (M+H)⁺; Anal. Calcd for C₂₃H₂₉ClN₆: C, 65.00; H, 6.88; N, 19.78; Found: C, 64.98; H, 6.90; N, 19.81; HPLC purity: 97.9 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-piperidin-1-yl-pyrimidin-4-yl)-hexane-1,6diamine (8d): Light brown solid; Yield: 82 %; mp 97-99 °C; IR (cm⁻¹, KBr): 3314, 2933, 1579, 1368, 1232, 1134, 983, 853, 789; ¹H NMR (400 MHz, CDCl₃): 1.47-1.64 (m, 12H), 1.72-1.79 (m,2H), 2.17 (s, 3H), 3.29 (q, 2H), 3.39 (q, 2H), 3.54 (t, 4H), 4.76 (brs, 1H), 5.07 (brs, 1H), 5.74 (s, 1H), 6.39 (d, 1H, J = 5.5 Hz), 7.34 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.67 (d, 1H, J = 8.7 Hz), 7.95 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 453.35 (M+H)⁺; Anal. Calcd for C₂₅H₃₃ClN₆: C, 66.28; H, 7.34; N, 18.55; Found: C, 66.32; H, 7.35; N, 18.49; HPLC purity: 96.9 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-morpholin-4-yl-pyrimidin-4-yl)-ethane-1,2diamine (8e): Pale yellow solid; Yield: 86 %; mp 165-167 °C; IR (cm⁻¹, KBr): 3391, 3245, 2954, 1585, 1438, 1228, 1110, 993; ¹H NMR (400 MHz, DMSO-*d*₆): 2.09 (s, 3H), 3.35-3.48 (m, 8H), 3.57 (t, 4H), 5.91 (s, 1H), 6.62-6.70 (m, 2H), 7.41 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.44 (brs, 1H), 7.74 (d, 1H, J = 2.3 Hz), 8.14 (d, 1H, J = 9.1 Hz), 8.35 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 399.20 (M+H)⁺; Anal. Calcd for C₂₀H₂₃ClN₆O: C, 60.22; H, 5.81; N, 21.07; Found: C, 60.34; H, 5.79; N, 21.09; HPLC purity: 90.8 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-morpholin-4-yl-pyrimidin-4-yl)-propane-1,3diamine (8f): White solid; Yield: 82 %; mp 165-167 °C; IR (cm⁻¹, KBr): 3233, 3063, 2954, 1576, 1366, 1247, 1123, 791; ¹H NMR (400 MHz, CDCl₃): 1.92 (quin, 2H), 2.20 (s, 3H), 3.39 (q, 2H), 3.47 (t, 4H), 3.52 (q, 2H), 3.66 (t, 4H), 5.22 (brs, 1H), 5.71 (s, 1H), 5.95 (brs, 1H), 6.34 (d, 1H, J = 5.4 Hz), 7.25 (dd, 1H, J = 11.0 Hz, 2.2 Hz), 7.72 (d, 1H, J = 8.7 Hz), 7.89 (d, 1H, J = 2.3 Hz), 8.44 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.10, 28.85, 38.56, 40.34, 44.09, 66.46, 92.27, 98.85, 117.35, 121.52, 124.93, 128.46, 134.73, 149.06, 149.90, 151.83, 161.87, 163.27, 165.70; ESI-MS (m/z): 413.21 (M+H)⁺; Anal. Calcd for C₂₁H₂₅ClN₆O: C, 61.08; H, 6.10; N, 20.35; Found: C, 61.12; H, 6.17; N, 20.40; HPLC purity: 99.5 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-morpholin-4-yl-pyrimidin-4-yl)-butane-1,4diamine (8g): White solid; Yield: 80 %; mp 214-216 °C; IR (cm⁻¹, KBr): 3256, 3066, 2964, 1583, 1367, 1245, 1122, 994, 790; ¹H NMR (400 MHz, CDCl₃): 1.72-1.80 (m, 2H), 1.83-1.91 (m, 2H), 2.20 (s, 3H), 3.36 (q, 2H), 3.48 (q, 2H), 3.52 (t, 4H), 3.71 (t, 4H), 4.83 (brs, 1H), 5.19 (brs,1H), 5.75 (s, 1H), 6.40 (d, 1H, J = 5.5 Hz), 7.32 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.63 (d, 1H, J = 8.7 Hz), 7.95 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 22.75, 24.18, 25.83, 41.39, 42.69, 64.93, 89.96, 97.19, 122.10, 122.28, 122.80, 126.34, 132.68, 147.77, 149.11, 150.43, 160.69, 161.99, 164.64; ESI-MS (m/z): 427.29 (M+H)⁺; Anal. Calcd for C₂₂H₂₇ClN₆O: C, 61.89; H, 6.37; N, 19.68; Found: C, 61.99; H, 6.45; N, 19.70; HPLC purity: 96.2 %

N-(7-Chloro-quinolin-4-yl)-N'-(6-methyl-2-morpholin-4-yl-pyrimidin-4-yl)-hexane-1,6diamine (8h): Pale yellow solid; Yield: 90 %; mp 107-109 °C; IR (cm⁻¹, KBr): 3245, 2935, 2855, 1579, 1366, 1220, 1123, 994, 789; ¹H NMR (400 MHz, CDCl₃): 1.44-1.46 (m, 4H), 1.55-1.62 (m, 2H), 1.69-1.74 (m, 2H), 2.20 (s, 3H), 3.27 (q, 2H), 3.36 (q, 2H), 3.54 (t, 4H), 3.78 (t, 4H), 4.88 (brs, 1H), 5.26 (brs, 1H), 5.73 (s, 1H), 6.37 (d, 1H, J = 5.1 Hz), 7.31 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.70 (d, 1H, J = 8.7 Hz), 7.93 (d, 1H, J = 2.2 Hz), 8.50 (d, 1H, J = 5.1 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.13, 26.62, 26.82, 28.66, 29.60, 41.04, 43.06, 44.09, 66.53, 91.58, 98.93, 117.07, 121.00, 125.08, 128.62, 134.67, 149.04, 149.68, 151.94, 162.00, 163.45, 166.31; ESI-MS (m/z): 456.21 (M+H)⁺; Anal. Calcd for C₂₄H₃₁ClN₆O: C, 63.35; H, 6.87; N, 18.47; Found: C, 63.29; H, 6.91; N, 18.46; HPLC purity: 99.5 %

N-(7-Chloro-quinolin-4-yl)-N'-[6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]ethane-1,2-diamine (8i): White solid 83 %; Yield: ; mp 134-136 °C; IR (cm⁻¹, KBr): 3385, 3066, 2940, 1581, 1445, 1305, 1139, 997, 793; ¹H NMR (400 MHz, CDCl₃): 2.29 (s, 3H), 2.30 (s, 3H), 2.42 (t, 4H), 3.41 (q, 2H), 3.62 (t, 4H), 3.84 (q, 2H), 5.51 (brs, 1H), 5.87 (s, 1H), 6.30 (d, 1H, J = 5.5 Hz), 6.90 (brs, 1H), 7.21 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.55 (d, 1H, J = 8.7 Hz), 7.89 (d, 1H, J = 2.3 Hz), 8.46 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 412.26 (M+H)⁺; Anal. Calcd for C₂₁H₂₆ClN₇: C, 61.23; H, 6.36; N, 23.80; Found: C, 61.18; H, 6.51; N, 23.85; HPLC purity: 99.4 %

N-(7-Chloro-quinolin-4-yl)-N'-[6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]propane-1,3-diamine (8j): Off white solid; Yield: 80 %; mp 176-178 °C; IR (cm⁻¹, KBr): 3257, 3065, 2938, 1580, 1369, 1236, 1142, 1001, 789; ¹H NMR (400 MHz, CDCl₃): 1.94 (quin, 2H), 2.21 (s, 3H), 2.28 (s, 3H), 2.36 (t, 4H), 3.42 (q, 2H), 3.52-3.56 (m, 6H), 5.32 (brs, 1H), 5.74 (s, 1H), 6.01 (brs, 1H), 6.37 (d, 1H, J = 5.4 Hz), 7.27 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.75 (d, 1H, J = 8.7 Hz), 7.91 (d, 1H, J = 2.3 Hz), 8.46 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 426.32 (M+H)⁺; Anal. Calcd for C₂₂H₂₈ClN₇: C, 62.03; H, 6.63; N, 23.02; Found: C, 62.11; H, 6.68; N, 22.95; HPLC purity: 99.3 %

N-(7-Chloro-quinolin-4-yl)-N'-[6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]butane-1,4-diamine (8k): White solid; Yield: 87 %; mp 183-185 °C; IR (cm⁻¹, KBr): 3248, 3072, 2927, 1581, 1367, 1280, 1139, 997, 790; ¹H NMR (400 MHz, CDCl₃): 1.75-1.91 (m, 4H), 2.19 (s, 3H), 2.29 (s, 3H), 2.39 (t, 4H), 3.36 (q, 2H), 3.48 (q, 2H), 3.56 (t, 4H), 4.86 (brs, 1H), 5.23 (brs, 1H), 5.77 (s, 1H), 6.39 (d, 1H, J = 5.5 Hz), 7.32 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.64 (d, 1H, J = 8.7 Hz), 7.94 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.15, 25.79, 27.65, 40.65, 43.04, 43.64, 46.10, 54.61, 92.00, 98.97, 117.12, 121.09, 125.09, 128.69, 134.67, 149.11, 149.68, 151.99, 162.13, 163.16, 166.16; ESI-MS (m/z): 440.33 (M+H)⁺; Anal. Calcd for C₂₃H₃₀ClN₇: C, 62.79; H, 6.87; N, 22.28; Found: C, 62.80; H, 6.85; N, 22.30; HPLC purity: 97.0 %

N-(7-Chloro-quinolin-4-yl)-N'-[6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-

hexane-1,6-diamine (81): Light brown solid; Yield: 85 %; mp 152-154 °C; IR (cm⁻¹, KBr): 3266, 3068, 2931, 1580, 1367, 1279, 1164, 993, 789; ¹H NMR (400 MHz, CDCl₃): 1.46-1.55 (m, 4H), 1.59-1.61 (m, 2H), 1.74-1.77 (m, 2H), 2.19 (s, 3H), 2.30 (s, 3H), 2.42-2.44 (m, 4H), 3.29 (q, 2H), 3.38 (q, 2H), 3.60 (t, 4H), 4.77 (brs, 1H), 5.02 (brs, 1H), 5.75 (s, 1H), 6.40 (d, 1H, J = 5.5 Hz), 7.35 (dd, 1H, J = 11.0 Hz, 2.1 Hz), 7.66 (d, 1H, J = 8.7 Hz), 7.95 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ¹³C NMR (100 MHz, CDCl₃): 24.14, 26.62, 26.82, 28.70, 29.63, 41.05, 43.10, 43.64, 46.12, 54.67, 91.72, 98.98, 117.08, 120.96, 125.14, 128.70, 134.71, 149.07, 149.67, 151.98, 162.05, 163.21, 166.09; ESI-MS (m/z): 468.32 (M+H)⁺; Anal. Calcd for C₂₅H₃₄ClN₇: C, 64.15; H, 7.32; N, 20.95; Found: C, 64.09; H, 7.31; N, 20.98; HPLC purity: 99.0 %

N-(7-Chloro-quinolin-4-yl)-N'-[2-(4-ethyl-piperazin-1-yl)-6-methyl-pyrimidin-4-yl]propane-1,3-diamine (8m): White solid; Yield: 82 %; mp 184-186 °C; IR (cm⁻¹, KBr): 3233, 2967, 2812, 1579, 1366, 1250, 1132, 998; ¹H NMR (400 MHz, CDCl₃): 1.10 (t, 3H), 1.95 (quin, 2H), 2.24 (s, 3H), 2.40-2.44 (m, 6H), 3.43 (q, 2H), 3.55-3.59 (m, 6H), 4.94 (brs, 1H), 5.78 (s, 1H), 5.92 (brs, 1H), 6.40 (d, 1H, J = 5.4 Hz), 7.30 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.73 (d, 1H, J = 8.7 Hz), 7.93 (d, 1H, J = 2.3 Hz), 8.49 (d, 1H, J = 5.4 Hz); ¹³C NMR (100 MHz, CDCl₃): 11.86, 24.38, 29.05, 38.50, 40.31, 43.64, 52.26, 52.34, 92.35, 98.85, 117.38, 121.47, 124.84, 128.53, 134.61, 149.15, 149.84, 151.94, 162.34, 163.04, 166.03; ESI-MS (m/z): 440.16 (M+H)⁺; Anal. Calcd for C₂₃H₃₀ClN₇: C, 62.79; H, 6.87; N, 22.28; Found: C, 62.75; H, 6.89; N, 22.20; HPLC purity: 99.6 %

N-(7-Chloro-quinolin-4-yl)-N'-[2-(4-ethyl-piperazin-1-yl)-6-methyl-pyrimidin-4-yl]butane-1,4-diamine (8n): White solid; Yield: 86 %; mp 101-103 °C; IR (cm⁻¹, KBr): 3255, 2939, 2813, 1583, 1372, 1249, 1127, 994, 791; ¹H NMR (400 MHz, CDCl₃): 1.09 (t, 3H), 1.73-1.80 (m, 2H), 1.84-1.91 (m, 2H), 2.19 (s, 3H), 2.38-2.43 (m, 6H), 3.35 (q, 2H), 3.48 (q, 2H), 3.57 (t, 4H), 4.83 (brs, 1H), 5.23 (brs, 1H), 5.77 (s, 1H), 6.39 (d, 1H, J = 5.5 Hz), 7.31 (dd, 1H, J = 11.0 Hz, 2.0 Hz), 7.64 (d, 1H, J = 8.7 Hz), 7.94 (d, 1H, J = 2.3 Hz), 8.51 (d, 1H, J = 5.5 Hz); ESI-MS (m/z): 454.35 (M+H)⁺; Anal. Calcd for C₂₄H₃₂ClN₇: C, 63.49; H, 7.10; N, 21.60; Found: C, 63.59; H, 7.18; N, 21.63; HPLC purity: 99.6 %

Assay for *in vitro* antimalarial activity and cytotoxicity

The antimalarial activity was determined by measuring plasmodial LDH activity as described earlier.¹ A suspension of red blood cells infected with D6 or W2 strain of *P. falciparum* (200

 μ L, with 2% parasitemia and 2% hematocrit in RPMI 1640 medium supplemented with 10% human serum and 60 µg/mL amikacin) was added to the wells of a 96- well plate containing 10 μ L of serially diluted test samples. The plate was flushed with a gas mixture of 90% N₂, 5% O₂, and 5% CO₂ and incubated at 37 °C, for 72 h in a modular incubation chamber (Billups-Rothenberg, CA). Parasitic LDH activity was determined according to the procedure of Makler and Hinrichs.² Briefly, 20 µL of the incubation mixture was mixed with 100 µL of the MalstatTM reagent (Flow Inc., Portland, OR) and incubated at room temperature for 30 min. Twenty microliters of a 1:1 mixture of NBT/PES (Sigma, St. Louis, MO) was then added and the plate is further incubated in the dark for 1 h. The reaction was then stopped by the addition of 100 µL of a 5% acetic acid solution. The plate was read at 650 nm. Artemisinin and chloroquine were included in each assay as antimalarial drug controls. IC_{50} values were computed from the dose response curves. To determine the selectivity index of antimalarial activity of compounds there in vitro cytotoxicity to mammalian cells was also determined. The assay was performed in 96-well tissue culture-treated plates as described earlier.³ Vero cells (monkey kidney fibroblasts) or PK1(pig kidney epithelial cells) or HepG2 (human hepatoma cells) were seeded to the wells of 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples at different concentrations were added and plates were again incubated for 48 h. The number of viable cells was determined by Neutral Red assay. IC₅₀ values were obtained from dose response curves. Doxorubicin was used as a positive control for cytotoxicity.

Crystallographic Data

Single crystal X-ray diffraction intensities for compound **8f** was collected on an Oxford CCD diffractometer having Xcalibur, sapphire diffraction measurement device at 293 K, using graphite-monochromated Mo-Ka radiation ($\lambda = 0.71073$ Å).⁴ The multi-scan absorption correction was applied using CrysalisPRO. The crystal structures were solved by the direct methods using SIR-92 and refined by full-matrix least-squares refinement techniques on F² using SHELXL97. Hydrogen atoms were placed into the calculated positions and included in the last cycles of the refinement. All calculations were done using WinGX software.⁵ CCDC 838496 contains the supplementary crystallographic data for compound **8f**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.





Figure 2: Crystal structure of compound 8f with partial numbering scheme. Thermal ellipsoidal are drawn at 40% probability level. Hydrogen atoms attached only to nitrogen atoms are shown for more clarity. Selected bond lengths [Å]: C9-N2 1.344(3), C10-N2 1.452(4), C12-N3 1.449(4), C13-N3 1.351(4), C16-N4 1.340(4), C16-N6 1.379(4), C16-N5 1.403(4); Selected bond angles [deg]: N4-C16-N6 116.2(3), N6-C16-N5 122.5(3), C9-N2-C10 121.9(2), C13-N3-C12 124.1(3).


	Compound 8f
Molecular formula	$C_{21}H_{25}CIN_6O$ (CHCl ₃ .H ₂ O)
Formula Weight	546.27
Temperature (K)	298(2)
Crystal system	triclinic
Space group	P -1
a (Å)	9.1519(5)
b (Å)	9.4906(4)
c (Å)	16.1562(8)
α [°]	74.799(4)
β [°]	75.567(5)
γ [°]	78.317(4)
V (Å3)	1297.25(11)
Ζ	2
d (g cm ⁻³)	1.399
F(000)	564
Goodness of fit (F ²)	1.031
$R_1, wR_2[I > 2(I)]^a$	$R_1 = 0.0686,$
	$wR_2 = 0.2009$
R ₁ , wR ₂ [all data] ^b	$R_1 = 0.0816,$
	$wR_2 = 0.2174$


 $\label{eq:rescaled_state} \begin{array}{l} {}^{a} R = \sum (\|F_{o}| - |F_{c}||) / \sum |F_{o}| \\ {}^{b} R_{w} = \{ \sum [w(F^{2}_{o} - F^{2}_{c})^{2}] / \sum [w(F^{2}_{o})^{2}] \}^{1/2} \end{array}$


References


- M. Jain, S. I. Khan, B. L. Tekwani, M. R. Jacob, S. Singh, P. P. Singh and R. Jain, Bioorg. *Med. Chem.*, 2005, **13**, 4458-4466.
- 2. M. T. Makler and D. J. Hinrichs, Am. J. Trop. Med. Hyg., 1993, 48, 205-210.
- 3. J. Mustafa, S. I. Khan, G. Ma, L. A. Walker and I. A. Khan, *Lipids*, 2004, **39**, 167-172.
- 4. CrysAlisPro, Oxford Diffraction Ltd., version 1.171.33.49b, 2009.
- 5. L. J. Farrugia, *WinGX*, version 1.64, *An Integrated System of Windows Programs for the Solution, Refinement and Analysis of Single-Crystal X-ray Diffraction Data*, Department of Chemistry, University of Glasgow, 2003.










































































































	Peak Results						
	Peak Name	RT	RT Ratio	Area (µV*sec)	% Area		
1	Peak1	1.96		296	0,01		
2	Peak2	2.51		4703	0.12		
3	Peak3	3.60	_	665	0.02		
4	Peak4	3.78		833	0.02		
5	Peak5	6.41		3240	0.08		
6	Peak6	13.94		3829961	97.17		
7	Peak7	15.11		12004	0.30		
8	Peak8	17.25		192	0.00		
9	Peak9	17.60		283	0.01		
10	Peak10	18.05		204	0.01		
11	Peak11	18.79		526	0.01		
12	Peak12	21.16		576	0.01		
13	Peak13	21.66		425	0.01		
14	Peak14	23.09		299	0.01		

	Peak Name	RT	RT Ratio	Area (µV*sec)	% Area
15	Peak15	24.87		7383	0.19
16	Peak16	25.65		24543	0.62
17	Peak17	26.50		20190	0.51
18	Peak18	28.82		16687	0.42
19	Peak19	32.01		615	0.02
20	Peak20	34.90		8828	0.22
21	Peak21	35.63		4569	0.12
22	Peak22	37.05		2684	0.07
23	Peak23	40.66		1633	0.04





I Car ICS dits						
	Peak Name	RT	RT Ratio	Area (µV*sec)	% Area	
1	Peak1	1.81		6690	0.11	
2	Peak2	2.51		15914	0.26	
3	Peak3	6.44		6017415	98.16	
4	Peak4	12.01		612	0.01	
5	Peak5	14.08		31038	0.51	
6	Peak6	16.50		321	0.01	
7	Peak7	17.74		320	0.01	
8	Peak8	21.64		29870	0.49	
9	Peak9	24.87		20706	0.34	
10	Peak10	25.68		207	0.00	
11	Peak11	31.65		3044	0.05	
12	Peak12	40.09		3972	0.06	

